Selected research
Industry Research
Herceptin Biosimilar Industry Research Report 2026
Market perspective
The global Herceptin Biosimilar market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Herceptin Biosimilar is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Herceptin Biosimilar is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Herceptin Biosimilar is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Herceptin Biosimilar include Mylan, Roche, Amgen, The Instituto Vital Brazil, Mabion, Genor Biopharma, Gedeon Richter, Celltrion and Biocon, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Herceptin Biosimilar market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Herceptin Biosimilar Market by Company
Mylan
Roche
Amgen
The Instituto Vital Brazil
Mabion
Genor Biopharma
Gedeon Richter
Celltrion
Biocon
AryoGen Biopharma
Herceptin Biosimilar Segment by Type
Leukemia
Colorectal Cancer
Lymphoma
Breast Cancer
Other
Herceptin Biosimilar Segment by Application
Hospital & Clinics
Oncology Centers
Other
Herceptin Biosimilar Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Herceptin Biosimilar market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Herceptin Biosimilar and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Herceptin Biosimilar.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Herceptin Biosimilar manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Herceptin Biosimilar by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Herceptin Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Leukemia
- Colorectal Cancer
- Lymphoma
- Breast Cancer
- Other
Applications
- Hospital & Clinics
- Oncology Centers
- Other
Companies covered
- Mylan
- Roche
- Amgen
- The Instituto Vital Brazil
- Mabion
- Genor Biopharma
- Gedeon Richter
- Celltrion
- Biocon
- AryoGen Biopharma
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Herceptin Biosimilar Market Size (2021-2032)
- 2.2.2 Global Herceptin Biosimilar Sales (2021-2032)
- 2.2.3 Global Herceptin Biosimilar Market Average Price (2021-2032)
- 2.3 Herceptin Biosimilar by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Leukemia
- 2.3.3 Colorectal Cancer
- 2.3.4 Lymphoma
- 2.3.5 Breast Cancer
- 2.3.6 Other
- 2.4 Herceptin Biosimilar by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital & Clinics
- 2.4.3 Oncology Centers
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Herceptin Biosimilar Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Herceptin Biosimilar Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Herceptin Biosimilar Revenue of Manufacturers (2021-2026)
- 3.4 Global Herceptin Biosimilar Average Price by Manufacturers (2021-2026)
- 3.5 Global Herceptin Biosimilar Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Herceptin Biosimilar, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Herceptin Biosimilar, Product Type & Application
- 3.8 Global Manufacturers of Herceptin Biosimilar, Established Date
- 3.9 Global Herceptin Biosimilar Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mylan
- 4.1.1 Mylan Company Information
- 4.1.2 Mylan Business Overview
- 4.1.3 Mylan Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mylan Herceptin Biosimilar Product Portfolio
- 4.1.5 Mylan Recent Developments
- 4.2 Roche
- 4.2.1 Roche Company Information
- 4.2.2 Roche Business Overview
- 4.2.3 Roche Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Roche Herceptin Biosimilar Product Portfolio
- 4.2.5 Roche Recent Developments
- 4.3 Amgen
- 4.3.1 Amgen Company Information
- 4.3.2 Amgen Business Overview
- 4.3.3 Amgen Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Amgen Herceptin Biosimilar Product Portfolio
- 4.3.5 Amgen Recent Developments
- 4.4 The Instituto Vital Brazil
- 4.4.1 The Instituto Vital Brazil Company Information
- 4.4.2 The Instituto Vital Brazil Business Overview
- 4.4.3 The Instituto Vital Brazil Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 The Instituto Vital Brazil Herceptin Biosimilar Product Portfolio
- 4.4.5 The Instituto Vital Brazil Recent Developments
- 4.5 Mabion
- 4.5.1 Mabion Company Information
- 4.5.2 Mabion Business Overview
- 4.5.3 Mabion Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Mabion Herceptin Biosimilar Product Portfolio
- 4.5.5 Mabion Recent Developments
- 4.6 Genor Biopharma
- 4.6.1 Genor Biopharma Company Information
- 4.6.2 Genor Biopharma Business Overview
- 4.6.3 Genor Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genor Biopharma Herceptin Biosimilar Product Portfolio
- 4.6.5 Genor Biopharma Recent Developments
- 4.7 Gedeon Richter
- 4.7.1 Gedeon Richter Company Information
- 4.7.2 Gedeon Richter Business Overview
- 4.7.3 Gedeon Richter Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Gedeon Richter Herceptin Biosimilar Product Portfolio
- 4.7.5 Gedeon Richter Recent Developments
- 4.8 Celltrion
- 4.8.1 Celltrion Company Information
- 4.8.2 Celltrion Business Overview
- 4.8.3 Celltrion Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Celltrion Herceptin Biosimilar Product Portfolio
- 4.8.5 Celltrion Recent Developments
- 4.9 Biocon
- 4.9.1 Biocon Company Information
- 4.9.2 Biocon Business Overview
- 4.9.3 Biocon Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Biocon Herceptin Biosimilar Product Portfolio
- 4.9.5 Biocon Recent Developments
- 4.10 AryoGen Biopharma
- 4.10.1 AryoGen Biopharma Company Information
- 4.10.2 AryoGen Biopharma Business Overview
- 4.10.3 AryoGen Biopharma Herceptin Biosimilar Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 AryoGen Biopharma Herceptin Biosimilar Product Portfolio
- 4.10.5 AryoGen Biopharma Recent Developments
5 Global Herceptin Biosimilar Market Scenario by Region
- 5.1 Global Herceptin Biosimilar Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Herceptin Biosimilar Sales by Region: 2021-2032
- 5.2.1 Global Herceptin Biosimilar Sales by Region: 2021-2026
- 5.2.2 Global Herceptin Biosimilar Sales by Region: 2027-2032
- 5.3 Global Herceptin Biosimilar Revenue by Region: 2021-2032
- 5.3.1 Global Herceptin Biosimilar Revenue by Region: 2021-2026
- 5.3.2 Global Herceptin Biosimilar Revenue by Region: 2027-2032
- 5.4 North America Herceptin Biosimilar Market Facts & Figures by Country
- 5.4.1 North America Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Herceptin Biosimilar Sales by Country (2021-2032)
- 5.4.3 North America Herceptin Biosimilar Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Herceptin Biosimilar Market Facts & Figures by Country
- 5.5.1 Europe Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Herceptin Biosimilar Sales by Country (2021-2032)
- 5.5.3 Europe Herceptin Biosimilar Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Herceptin Biosimilar Market Facts & Figures by Country
- 5.6.1 Asia Pacific Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Herceptin Biosimilar Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Herceptin Biosimilar Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Herceptin Biosimilar Market Facts & Figures by Country
- 5.7.1 South America Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Herceptin Biosimilar Sales by Country (2021-2032)
- 5.7.3 South America Herceptin Biosimilar Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Herceptin Biosimilar Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Herceptin Biosimilar Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Herceptin Biosimilar Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Herceptin Biosimilar Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Herceptin Biosimilar Sales by Type (2021-2032)
- 6.1.1 Global Herceptin Biosimilar Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Herceptin Biosimilar Sales Market Share by Type (2021-2032)
- 6.2 Global Herceptin Biosimilar Revenue by Type (2021-2032)
- 6.2.1 Global Herceptin Biosimilar Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Herceptin Biosimilar Revenue Market Share by Type (2021-2032)
- 6.3 Global Herceptin Biosimilar Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Herceptin Biosimilar Sales by Application (2021-2032)
- 7.1.1 Global Herceptin Biosimilar Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Herceptin Biosimilar Sales Market Share by Application (2021-2032)
- 7.2 Global Herceptin Biosimilar Revenue by Application (2021-2032)
- 7.2.1 Global Herceptin Biosimilar Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Herceptin Biosimilar Revenue Market Share by Application (2021-2032)
- 7.3 Global Herceptin Biosimilar Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Herceptin Biosimilar Value Chain Analysis
- 8.1.1 Herceptin Biosimilar Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Herceptin Biosimilar Production Mode & Process
- 8.2 Herceptin Biosimilar Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Herceptin Biosimilar Distributors
- 8.2.3 Herceptin Biosimilar Customers
9 Global Herceptin Biosimilar Analyzing Market Dynamics
- 9.1 Herceptin Biosimilar Industry Trends
- 9.2 Herceptin Biosimilar Industry Drivers
- 9.3 Herceptin Biosimilar Industry Opportunities and Challenges
- 9.4 Herceptin Biosimilar Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst